The fact that the dimerization is essential for Hakai activity as an E3 ubiquitin ligase suggests that allosteric inhibitors targeting the HYB domain have potential therapeutic implications for tumor treatment [14]. This evidence concerns the gene CBLL1 and neoplasm.